Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablaris' peptide slims fat monkeys, but will its apoptosis mechanism fly in humans?

This article was originally published in Scrip

Executive Summary

The publication on 10 November 2011 of a preclinical study that showed that rhesus monkeys can lose an average of 11% of their body mass when treated with a peptide called adipotide caused a great deal of general media interest and the share value of Arrowhead Research to rise some 40% on the day. The compound also showed some potential in lowering insulin requirements. However, with the FDA in the process of deciding whether the compound’s can enter human trials, its apoptotic mechanism of action may make mean that FDA will take a particular interest in the compound's safety profile.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015178

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel